There are currently 27 clinical trials in Sherman, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Cancer Center - Sherman, Sherman Clinical Research, Texas Oncology-Sherman and Texas Institute for Neurological Disorders. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769
Recruiting
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
04/10/2025
Locations: Sherman Clinical Research - ClinEdge - PPDS, Sherman, Texas
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each particip... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
04/10/2025
Locations: Teva Investigational Site 15647, Sherman, Texas
Conditions: Asthma
Register for Updates
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/09/2025
Locations: Texas Institute for Neurological Disorders, Sherman, Texas
Conditions: Migraine
Register for Updates
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
NCT06675175
Recruiting
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: Research Site, Sherman, Texas
Conditions: Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Revival Research Corporation - Sherman - ClinEdge - PPDS, Sherman, Texas
Conditions: Primary IgA Nephropathy
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/03/2025
Locations: Research Site, Sherman, Texas
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Cardiovoyage, Sherman, Texas
Conditions: Acute Coronary Syndrome
Register for Updates
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Texas Institute for Neurological Disorders, Sherman, Texas
Conditions: Parkinson's Disease
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: North Texas Surgery Center, Sherman, Texas
Conditions: Lumbar Spinal Stenosis
Register for Updates
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012
Recruiting
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/01/2025
Locations: Revival Research Institute LLC, Sherman, Texas
Conditions: Depressive Disorder, Major
Register for Updates
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
NCT06343298
Recruiting
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2025
Locations: Revival Research, Sherman, Texas
Conditions: Difficult to Control Hypertension
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/27/2025
Locations: Texas Institute for Neurological Disorders, Sherman, Texas
Conditions: Relapsing Multiple Sclerosis
Register for Updates